Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral develops devices for unmet medical needs. Sepsis occurs in 1.7M Americans/year causing 250K deaths, often caused by endotoxin. Our devices measure and remove endotoxin from the bloodstream. An FDA confirmatory trial is underway. Dialco, a Spectral sub, offers SAMI, a novel instrument for renal replacement, cleared by FDA. Dialco is seeking FDA approval for DIMI a unique home dialysis enabler. These devices have large commercial potential


TSX:EDT - Post by User

Comment by Gorf79on Jul 28, 2022 4:57pm
186 Views
Post# 34858255

RE:So what does exceeding expectations mean…

RE:So what does exceeding expectations mean…

I'm gonna go with 47%!


If you are going to publicly state, on many occasions, that you are "exceeding expectations",  a 47% mortality benefit seems about right... if not a bit light in this highly personalized environment...

I believe the Euphrates sub group demonstrated a 29% mortality benefit, so I'm benchmarking off of that for the original " expectation" of the Tigris trial.

<< Previous
Bullboard Posts
Next >>